Canagliflozin (hemihydrate): High-Purity SGLT2 Inhibitor for Advanced Glucose Metabolism Research

Executive Summary: Canagliflozin (hemihydrate) is a research-grade, high-purity SGLT2 inhibitor validated for studies of renal glucose reabsorption and diabetes mellitus (APExBIO). Its mechanism involves selective inhibition of sodium-glucose co-transporter 2, directly promoting urinary glucose excretion and lowering blood glucose. In controlled yeast-based growth assays, canagliflozin shows no evidence of mTOR pathway inhibition, thereby ensuring pathway specificity (Breen et al., 2025). It is supplied as a hemihydrate with high solubility in DMSO and ethanol, making it compatible with diverse in vitro protocols. This article provides atomic, verifiable facts and clarifies the best practices and limitations for deploying canagliflozin in metabolic disorder research.

Biological Rationale

Glucose homeostasis is central to metabolic health and diabetes mellitus research. The kidney reabsorbs filtered glucose via sodium-glucose co-transporters, mainly SGLT2, which recovers over 90% of filtered glucose in the proximal tubule. Inhibiting SGLT2 reduces renal glucose reabsorption, leading to glucosuria and lower systemic glucose levels—a validated therapeutic and experimental approach (APExBIO). Canagliflozin (hemihydrate), also known as JNJ 28431754 hemihydrate, is a potent small molecule targeting this precise step. Its use in research enables mechanistic studies of glucose excretion, homeostasis, and the evaluation of diabetes interventions. Unlike mTOR inhibitors such as rapamycin, canagliflozin does not modulate mTORC1 or mTORC2 signaling pathways, isolating its effects to glucose transport mechanisms (Breen et al., 2025).

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) functions as a selective inhibitor of the sodium-glucose co-transporter 2 (SGLT2), classified as a small molecule SGLT2 inhibitor for diabetes research. Its chemical formula is C24H26FO5.5S, molecular weight 453.52 Da. Canagliflozin binds to SGLT2 in the renal proximal tubule, competitively blocking glucose and sodium reabsorption. This increases urinary glucose excretion and reduces blood glucose concentrations (APExBIO). It is insoluble in water but has high solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL), facilitating versatile in vitro and ex vivo assay integration. Canagliflozin (hemihydrate) is not a substrate or inhibitor for mTOR, as demonstrated in yeast-based and mammalian pathway assays (Breen et al., 2025). Its direct effect on glucose transport makes it a precise tool for dissecting glucose homeostasis pathways.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) inhibits SGLT2-mediated renal glucose reabsorption, promoting glucosuria and lowering blood glucose in in vitro and preclinical models (APExBIO).
• Validated high purity (≥98%) by HPLC and NMR; molecular identity confirmed and batch-specific QC is standard (APExBIO).
• No evidence for mTOR pathway inhibition observed in drug-sensitized yeast models at concentrations up to 100 μM (Breen et al., 2025).
• Solubility profile: soluble in DMSO (≥83.4 mg/mL), ethanol (≥40.2 mg/mL), insoluble in water; stable at -20°C (APExBIO).
• Recommended for glucose metabolism research, diabetes mellitus modeling, and studies of renal glucose dynamics (related article).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) is widely used in studies of glucose metabolism, SGLT2 function, and diabetes mellitus models. Its high selectivity for SGLT2 makes it ideal for dissecting renal glucose handling and evaluating anti-hyperglycemic interventions. It is not recommended for studies targeting mTOR, TORC1/2, or non-glucose metabolic pathways. Unlike agents such as rapamycin, it does not suppress cell proliferation or longevity pathways (Breen et al., 2025).

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) does not inhibit mTOR signaling or induce TOR1-dependent growth inhibition in yeast or mammalian systems (Breen et al., 2025).
• It is not a general inhibitor of all glucose transporters; specificity is predominantly for SGLT2 over SGLT1.
• Solutions of canagliflozin (hemihydrate) should not be stored long-term; prepare fresh for each experiment to maintain efficacy (APExBIO).
• It is intended solely for research use; not for diagnostic or therapeutic applications.
• Solubility is low in aqueous media; always use recommended organic solvents for stock solutions.

This article updates and clarifies Canagliflozin Hemihydrate: Precision SGLT2 Inhibition and... by providing explicit evidence for lack of mTOR pathway activity. For a systems-biology view integrating translational applications, see Canagliflozin (Hemihydrate): Unlocking Next-Gen SGLT2 Inh..., which this article extends by focusing on experimental boundaries and specificity. For cell-assay optimization and vendor reliability, refer to Optimizing Cell-Based Assays with Canagliflozin (hemihydr...; here we emphasize mechanistic boundaries and negative controls.

Workflow Integration & Parameters

Canagliflozin (hemihydrate) is supplied as a high-purity powder (SKU C6434) by APExBIO, shipped on blue ice and recommended for storage at -20°C. Solubilize in DMSO or ethanol at concentrations up to 83.4 mg/mL and 40.2 mg/mL, respectively. Prepare working solutions fresh before each experiment; avoid prolonged storage to prevent degradation. For cell-based assays, titrate to desired final concentrations (typically 0.1–10 μM) in culture media, ensuring final DMSO or ethanol concentrations do not exceed 0.1–0.5% to avoid solvent toxicity. For glucose metabolism studies, include appropriate SGLT1 controls to verify selectivity. Confirm compound identity and purity by HPLC/NMR as per product certificate. Reference the C6434 kit for detailed technical documentation.

Conclusion & Outlook

Canagliflozin (hemihydrate) is a validated, high-purity SGLT2 inhibitor for research on renal glucose reabsorption and diabetes mellitus. It offers selectivity and reproducibility for studies of glucose homeostasis, with no mTOR inhibitory activity in established models (Breen et al., 2025). Researchers should deploy it in protocols requiring precise SGLT2 inhibition, leveraging its robust QC and compatibility with standard solvents. For further technical guidance or batch-specific details, consult APExBIO and referenced internal resources.